NasdaqGM - Nasdaq Real Time Price USD

Tema Neuroscience And Mental Health ETF (MNTL)

26.29 +0.00 (+0.02%)
As of 9:30 AM EST. Market Open.
Loading Chart for MNTL
DELL
  • Previous Close 26.29
  • Open 26.29
  • Bid --
  • Ask --
  • Day's Range 26.29 - 26.29
  • 52 Week Range 23.67 - 27.66
  • Volume 714
  • Avg. Volume 312
  • Net Assets 11.59M
  • NAV 26.28
  • PE Ratio (TTM) --
  • Yield --
  • YTD Daily Total Return --
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.75%

Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.

Tema Global Limited

Fund Family

Health

Fund Category

11.59M

Net Assets

2024-01-22

Inception Date

Performance Overview: MNTL

View More

Trailing returns as of 11/1/2024. Category is Health.

YTD Return

MNTL
0.00%
Category
10.57%
 

1-Year Return

MNTL
0.00%
Category
21.36%
 

3-Year Return

MNTL
0.00%
Category
0.43%
 

People Also Watch

Holdings: MNTL

View More

Top 10 Holdings (46.95% of Total Assets)

SymbolCompany% Assets
VRTX
Vertex Pharmaceuticals Incorporated 6.55%
DNLI
Denali Therapeutics Inc. 5.44%
LLY
Eli Lilly and Company 5.39%
REGN
Regeneron Pharmaceuticals, Inc. 5.28%
ARGX
argenx SE 4.67%
ALNY
Alnylam Pharmaceuticals, Inc. 4.46%
TEVA
Teva Pharmaceutical Industries Limited 3.99%
NBIX
Neurocrine Biosciences, Inc. 3.82%
BIIB
Biogen Inc. 3.75%
UCB.BR
UCB SA 3.59%

Sector Weightings

SectorMNTL
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Related ETF News

View More

Research Reports: MNTL

View More
  • Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins, Leading to Valuation Increase

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • Daily – Vickers Top Insider Picks for 04/24/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 04/19/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 04/12/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

Related Tickers